A new biotechnological process, exploiting scaffold synthetic repertoires will be developed to profile cancer cells by polemics, interfere with cancer phenotypes, rationally design drugs. The selected scaffold is the SH2 domain, an interaction surface, which binds to phosphotyrosine (pie)-containing peptides. By random autogenesis of five critical residues in the domain we have created library theoretically able to bind every containing-containing protein. This library will be used to
a) identify novel specificities of synthetic SH2 domains,
b) molecularly dissect the SH2: pY-peptide interaction,
c) purify novel pY-proteins,
d) interfere with phenotypes such as proliferation, differentiation and apoptosis,
e) profile containing patterns in cancer, f) develop peptide antagonists. The involvement of the SH2: pY interaction, in TK-mediated signalling, predicts application of this bioprocess to other pathological conditions, in addition to cancer, involving aproliferative/signaling component.
Funding SchemeCSC - Cost-sharing contracts
WC2A 3NL London